Trump reclassifies marijuana to Schedule III to boost medical research

The Trump administration moved to shift marijuana from Schedule I to Schedule III to expand medical research access, limited to FDA-approved products or state-legal medical cannabis, with an administrative hearing set for June 29 to speed broader rescheduling. The move, rooted in a December executive order, does not legalize cannabis federally but includes tax relief for cannabis companies and could lend legitimacy to regulated medical programs. Reactions are mixed: supporters praise the shift as overdue progress, while some Republicans and critics worry it may advance industry interests over public health.